Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 52

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 52
---
     |      |     |   |
|                                                                           |     |     |      |     | $ |

A $0.10 increase in the assumed
combined public offering price of $ per share and accompanying
warrant (the last reported sale price of our common stock on The Nasdaq Capital Market on August ,
2025) would result in an increase in our as adjusted net tangible book value after this offering of approximately $ million,
or approximately $ per share, and the dilution per share to investors
purchasing common stock and accompanying warrants in this offering would be approximately $ per
share, assuming that the number of shares of our common stock and accompanying warrants sold by us remains the same, after deducting the
placement agent fees and estimated offering expenses payable by us. Similarly, a decrease of $0.10 in the assumed combined public offering
price of $ per share and accompanying warrant would result in a decrease in our as adjusted net
tangible book value after this offering of approximately $ million,
or approximately $ per share, and the dilution per share to investors
purchasing common stock and accompanying warrants in this offering would be $ per
share, assuming that the number of shares of our common stock and accompanying warrants sold by us remains the same, after deducting the
placement agent fees and estimated offering expenses payable by us.

We may also increase or decrease
the number of shares of common stock and accompanying warrants we are offering from the number of shares of common stock and accompanying
warrants set forth above. An increase of 1.0 million in the assumed number of shares of common stock and accompanying warrants sold
by us in this offering would result in an increase in our as adjusted net tangible book value of approximately $
million, or approximately $ per share, and the dilution per share
to investors purchasing common stock and accompanying warrants in this offering would be approximately $
per share, assuming that the assumed combined public offering price per share of common stock and accompanying warrant remains the same,
after deducting the placement agent fees and estimated offering expenses payable by us. A decrease of 1.0 million in the assumed
number of shares of common stock and accompanying warrants sold by us in this offering would result in a decrease in our as adjusted net
tangible book value after this offering of approximately $ million,
or approximately per share, and the dilution per share to investors purchasing common stock and accompanying warrants in this offering
would be approximately $ per share, assuming that the assumed
combined public offering price per share